Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.
J Y Borg, … , J Caen, R W Carrell
J Y Borg, … , J Caen, R W Carrell
Published April 1, 1988
Citation Information: J Clin Invest. 1988;81(4):1292-1296. https://doi.org/10.1172/JCI113447.
View: Text | PDF
Research Article

Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

  • Text
  • PDF
Abstract

Antithrombin Rouen-II, a new inherited variant of antithrombin-III, was found in two members of a family with no definite history of thrombosis. The subjects had normal antigenic concentrations of antithrombin and normal progressive inhibitory activity. However, the variant had defective heparin and heparan sulfate cofactor activities, and was not activated by a synthetic pentasaccharide representing the minimum heparin sequence. The abnormal antithrombin was isolated using heparin-Sepharose chromatography, and on electrophoresis at pH 8.6 migrated more anodally than normal. Two-dimensional peptide mapping of tryptic and Staphylococcus aureus V8 protease digests was performed and the abnormal peptide was located by tryptophan staining. Amino acid sequence studies demonstrated a substitution of arginine at residue 47 by a serine. Evidence strongly suggests that arginine 47 is a prime heparin binding site in antithrombin and that it forms part of a proposed positively charged linear site (to which heparin binds) that stretches across the surface of the molecule from the A to the D helix.

Authors

J Y Borg, M C Owen, C Soria, J Soria, J Caen, R W Carrell

×

Total citations by year

Year: 2024 2013 2012 2008 2006 2005 2001 1999 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1986 Total
Citations: 1 1 1 1 1 1 1 1 4 5 4 6 1 9 8 8 6 1 1 61
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (61)

Title and authors Publication Year
Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics
Balogh G, Bereczky Z
Biomolecules 2024
Polymeric Biomaterials: Medicinal and Pharmaceutical Applications, Volume 2
S Deshayes, K Gionnet, V Maurizot, G Déléris
Polymeric Biomaterials: Medicinal and Pharmaceutical Applications, Volume 2 2013
Production of Plasma Proteins for Therapeutic Use: Bertolini/Plasma Proteins
S Chtourou, M Poulle
Production of Plasma Proteins for Therapeutic Use: Bertolini/Plasma Proteins 2012
Biomaterials Fabrication and Processing Handbook
LR Berry, AK Chan
Biomaterials Fabrication and Processing Handbook 2008
Women's Vascular Health
R Lindsay
Women's Vascular Health 2006
Chemistry and Biology of Heparin and Heparan Sulfate
JM Walenga, WP Jeske, J Fareed
Chemistry and Biology of Heparin and Heparan Sulfate 2005
Polymeric Biomaterials, Revised and Expanded
L Berry, M Andrew, A Chan
Polymeric Biomaterials, Revised and Expanded 2001
Hämostaseologie
G Müller-Berghaus, B Pötzsch
Hämostaseologie 1999
The anticoagulant activation of antithrombin by heparin
L Jin, JP Abrahams, R Skinner, M Petitou, RN Pike, RW Carrell
Proceedings of the National Academy of Sciences 1997
BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE
JM Walenga, WP Jeske, L Bara, MM Samama, J Fareed
Thrombosis Research 1997
The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site
R Skinner, JP Abrahams, JC Whisstock, AM Lesk, RW Carrell, MR Wardell
Journal of Molecular Biology 1997
Chemistry and Biology of Serpins
FC Church, DD Cunningham, D Ginsburg, M Hoffman, SR Stone, DM Tollefsen
1997
Review
M Epstein
Renal Failure 1996
Molecular genetics of human antithrombin deficiency
DJ Perry, RW Carrell
Human Mutation 1996
Molecular genetics of antithrombin deficiency
DA Lane, G Kunz, RJ Olds, SL Thein
Blood Reviews 1996
Role of Arginine 132 and Lysine 133 in Heparin Binding to and Activation of Antithrombin
JL Meagher, JA Huntington, B Fan, PG Gettins
The Journal of biological chemistry 1996
Cardiovascular Science in France
K Schwartz, M Aiach
Trends in Cardiovascular Medicine 1996
Antithrombins Southport (Leu 99 to Val) and Vienna (Cln 118 to Pro): two novel antithrombin variants with abnormal heparin binding
V Chowdhury, B Mille, RJ Olds, DA Lane, J Watton, TW Barrowcliffe, I Pabinger, BE Woodcock, SL Thein
British Journal of Haematology 1995
What do dysfunctional serpins tell us about molecular mobility and disease?
PE Stein, RW Carrell
Nature Structural Biology 1995
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin
WP Sheffield, MA Blajchman
FEBS Letters 1995
Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the .beta.-antithrombin III isoform with enhanced heparin affinity
V Picard, E Ersdal-Badju, SC Bock
Biochemistry 1995
THE MOLECULAR GENETICS OF ANTITHROMBIN DEFICIENCY
RJ Olid, D A.Lane, SL Thein
British Journal of Haematology 1994
Antithrombin and its inherited deficiencies
DJ Perry
Blood Reviews 1994
Conformational Change in Antithrombin Induced by Heparin, Probed with a Monoclonal Antibody against the 1C/4B Region
J Dawes, K James, DA Lane
Biochemistry 1994
Arg-129 plays a specific role in the confirmation of antithrombin and in the enhancement of factor Xa inhibition by the pentasaccharode sequence of heparin
S Najjam, G Chadeuf, S Gandrille, M Aiach
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1994
Three novel mutations of antithrombin inducing high-molecular-mass compounds
J Emmerich, D Vidaud, M Alhenc-Gelas, G Chadeuf, M Gouault-Heilmann, MF Aillaud, M Aiach
Arteriosclerosis Thrombosis and Vascular Biology 1994
Role of N- and C-terminal amino acids in antithrombin binding to pentasaccharide
B Mille, J Watton, TW Barrowcliffe, JC Mani, DA Lane
The Journal of biological chemistry 1994
Heparin binding affinity of normal and genetically modified antithrombin III measured using a monoclonal antibody to the heparin binding site of antithrombin III
J Watton, C Longstaff, DA Lane, TW Barrowcliffe
Biochemistry 1993
Pleiotropic effects of antithrombin strand 1C substitution mutations
DA Lane, RJ Olds, J Conard, M Boisclair, SC Bock, M Hultin, U Abildgaard, H Ireland, E Thompson, G Sas
Journal of Clinical Investigation 1992
Serpins: Mobile conformations in a family of proteinase inhibitors
RW Carrell, DL Evans
Current Opinion in Structural Biology 1992
Antithrombin Budapest 3 An antithrombin variant with reduced heparin affinity resulting from the substitution L99F
RJ Olds, DA Lane, M Boisclair, G Sas, SC Bock, SL Thein
FEBS Letters 1992
Expression and mutagenesis of thrombospondin
J Lawler, P Ferro, M Duquette
Biochemistry 1992
Heparin binding site, conformational change, and activation of antithrombin
DL Evans, CJ Marshall, PB Christey, RW Carrell
Biochemistry 1992
Cerebral infarction in a heterozygote with variant antithrombin III
T Arima, M Motomura, Y Nishiura, M Tsujihata, K Okajima, H Abe, S Nagataki
Stroke; a journal of cerebral circulation 1992
Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin
HJ Ehrlich, RK Gebbink, J Keijer, H Pannekoek
The Journal of biological chemistry 1992
Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor
I Björk, K Ylinenjärvi, ST Olson, PE Bock
The Journal of biological chemistry 1992
Role of tryptophan 49 in the heparin cofactor activity of human antithrombin III
P Gettins, J Choay, BC Crews, G Zettlmeiss
The Journal of biological chemistry 1992
The molecular genetics of familial venous thrombosis
DN Cooper
Blood Reviews 1991
Novel point mutations leading to type 1 antithrombin deficiency and thrombosis
RJ Olds, DA Lane, H Ireland, G Leone, VD Stefano, ML Wiesel, JP Cazenave, SL Thein
British Journal of Haematology 1991
Antithrombin III-Amiens: A new family with an Arg47 → cys inherited variant of antithrombin iii with impaired heparin cofactor activity
B Roussel, J Dieval, J Delobel, F Fernandez-Rachubinski, B Eng, RA Rachubinski, MA Blajchman
American Journal of Hematology 1991
P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase Implications for the heparin activation mechanism
MC Owen, PM George, DA Lane, DR Boswell
FEBS Letters 1991
The tammar wallaby major plasma serpin: Partial characterization including the sequence of the reactive site region
SD Patterson, K Bell, DC Shaw
Comparative Biochemistry and Physiology Part C: Comparative Pharmacology 1991
Functional antithrombin-III variant (41 pro→leu) identified by liquid secondary ion mass spectrometry
SO Brennan, JY Borg, GJ Shaw, J Caen, PM George
Pathology 1991
Recombinant Technology in Hemostasis and Thrombosis
LW Hoyer, WN Drohan
1991
Role of lysine 173 in heparin binding to heparin cofactor II
HC Whinna, MA Blinder, M Szewczyk, DM Tollefsen, FC Church
The Journal of biological chemistry 1991
Clinical and biochemical characterization of antithrombin III Franconville, a variant with Pro 41 Leu mutation
N Roux, G Chadeuf, P Molho-Sabatier, PF Plouin, M Aiach
British Journal of Haematology 1990
Antithrombin III: structural and functional aspects
L Mourey, JP Samama, M Delarue, J Choay, JC Lormeau, M Petitou, D Moras
Biochimie 1990
Antithrombin Rouen-IV 24 Arg→Cys The amino-terminal contribution to heparin binding
JY Borg, SO Brennan, RW Carrell, P George, DJ Perry, J Shaw
FEBS Letters 1990
Antithrombin III
CH Beresford, MC Owen
International Journal of Biochemistry 1990
Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin
BA Owen, WG Owen
Biochemistry 1990
New Trends in Haemostasis
J Harenberg, DL Heene, G Stehle, G Schettler
1990
Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine
S Gandrille, M Aiach, DA Lane, D Vidaud, P Molho-Sabatier, R Caso, P de Moerloose, JN Fiessinger, E Clauser
The Journal of biological chemistry 1990
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins:
M Verstraete
Drugs 1990
Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation
P Molho-Sabatier, M Aiach, I Gaillard, JN Fiessinger, AM Fischer, G Chadeuf, E Clauser
Journal of Clinical Investigation 1989
9 Antithrombin: Structure, genomic organization, function and inherited deficiency
DA Lane, R Caso
Baillière's Clinical Haematology 1989
Implications of the three-dimensional structure of .alpha.1-antitrypsin for structure and function of serpins
R Huber, RW Carrell
Biochemistry 1989
Heparin Cofactor IIOslo
MA Blinder, TR Andersson, U Abildgaard, DM Tollefsen
The Journal of biological chemistry 1989
Antithrombin Activity of Fucoidan
FC Church, JB Meade, RE Treanor, HC Whinna
The Journal of biological chemistry 1989
A novel amino acid substitution in the reactive site of a congenital variant antithrombin
DA Lane, H Erdjument, E Thompson, M Panico, VD Marzo, HR Morris, G Leone, VD Stefano, SL Thein
The Journal of biological chemistry 1989
New carbohydrate site in mutant antithrombin (7 Ile→Asn) with decreased heparin affinity
SO Brennan, JY Borg, PM George, C Soria, J Soria, J Caen, RW Carrell
FEBS Letters 1988
Thrombin
JW Fenton
Annals of the New York Academy of Sciences 1986

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts